Dialectic Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vesalio hires J.D. McCulloch as Chief Financial Officer and announces the establishment of the company’s headquarters in Dallas, Texas.

Zuora, Inc. , a leading monetization suite for modern business, today announced the appointment of John D. Harkey, Jr. to the Zuora Board of Directors, effective April 30, 2024. With the addition of...

New York, USA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Peripheral T-Cell Lymphoma Market to Observe Growth at a CAGR of 4.9% in the US by 2032 | DelveInsight The rapid growth in the peripheral T-cell lymphoma market

Peripheral T-cell lymphoma (PTCL) is an aggressive and uncommon type of non-Hodgkin lymphoma. Genetic research has led to improving understanding of...

Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216 News provided by Share this article DALLAS, March 3, 2021 /PRNewswire/ -- Dialectic Therapeutics, Inc. (Dialectic ®), a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel A...